Adalvo announces completion of Phase III patient enrollment for Dimethyl Fumarate 30 mg / 120 mg

18 August 2021

Adalvo is pleased to announce that we have completed our patient enrollment of our Phase 3 clinical study, to assess the safety and efficacy of Dimethyl Fumarate 30 mg / 120 mg hard capsules, which is being developed in collaboration with one of our strategic partners.

Our product is used in the treatment of psoriasis and we are happy to bring this alternative treatment to patients in need.

Adalvo is looking forward to becoming the only company offering this value-added product, several years before any alternative competitor. We continue to make investments to broaden our generic landscape and enhance the value for our partners.